Search

392 Result(s)
Sort by

Innovation in medicinal chemistry

Innovation in medicinal chemistry

Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
Generalized pustular psoriasis at EADV 2021

Generalized pustular psoriasis at EADV 2021

Dr. Emmanuelle Clerisme-Beaty (former Associate Head of Medicine - Inflammation, Boehringer Ingelheim) reflects on developments for GPP at the EADV congress, 2021
Keep water clean

Keep water clean

Human beings can’t survive without water. Further, the safe production of medicines depends on clean drinking water.
Biotherapeutics Discovery

Biotherapeutics Discovery

We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Aiko Watabe

Aiko Watabe

Aiko Watabe, Medicine & Regulatory Affairs, describes a career at Boehringer Ingelheim.
Lung Repair & Regeneration Video

Lung Repair & Regeneration Video

Lung repair & regeneration research addresses fundamental changes to lung architecture and how these changes impact lung function.
NEJM-IL-36-Phase-1-GPP-data

NEJM-IL-36-Phase-1-GPP-data

Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
BIVF funding more than doubled to 250 M€

BIVF funding more than doubled to 250 M€

Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Patient Organizations

Patient Organizations

Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Research Beyond Borders Partnering

Research Beyond Borders Partnering

Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Embracing diversity in clinical trials

Embracing diversity in clinical trials

At Boehringer Ingelheim, we understand the crucial need of embracing diversity in clinical trials as an opportunity to enable more equitable healthcare.
CHMP_opinion_Nintedanib_SSc-ILD

CHMP_opinion_Nintedanib_SSc-ILD

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Ruminant parasite control in a nutshell

Ruminant parasite control in a nutshell

An exclusive drug-based approach to fight worms is dying. Dr. Ray Kaplan, from Georgia University, explains five things you need to know.
Boehringer Ingelheim Innovation Prize

Boehringer Ingelheim Innovation Prize

Find out more about how we’re providing valuable resources to life-science innovators to enable new and emerging science
Protein Degraders in Cancer

Protein Degraders in Cancer

Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
COVID-19 Protecting Our Employees

COVID-19 Protecting Our Employees

Boehringer Ingelheim has taken precautions to protect the health of employees and mitigate the risk of COVID-19 affecting our organization.